No significant difference of gender, age, level of anti-GBM autoantibodies, serum creatinine, or other clinical and pathological parameters was found between anti-GBM patients with and without HLA-DPB1*0401 (Table 2). This evidence concerns the gene HLA-DPB1 and glioblastoma.